Overview

With advanced research, we create innovative vaccines and bio-therapeutics for a healthier tomorrow.


Bharat Biotech creates innovative vaccines and bio-therapeutics trusted by physicians around the world. We own 50 global patents and our products help people in over 65 countries live to their fullest potential. Our manufacturing facilities are approved by USFDA, KFDA and WHO.

We have delivered over 3 billion vaccine doses all over the world. Our key priority is to solve the health challenges of the developing world by developing innovative vaccines and therapeutics

From our early years, we invested in cutting-edge research in areas that need urgent medical solutions. This focus saw a succession of effective vaccines leave our labs and have a lasting impact on the health of millions. Our significant R&D investments have yielded several breakthroughs including the world’s first:


  • Eco-friendly recombinant Hepatitis-B vaccine (free of cesium chloride and Thiomersal)
  • Rotavirus vaccine from a naturally attenuated strain
  • Typhoid Conjugate vaccine

We have delivered over 3 billion vaccine doses all over the world. REGEN-D®—our epidermal growth factor for diabetic foot ulcers and burnsis a leading product in the wound healing segment. Our key priority is to solve the health challenges of the developing world. We were among the first to develop vaccines for viral diseases like Chikangunya and Zika.


Transparency and openness are central to our DNA. An uncompromising commitment to integrity differentiates us. Our clinical trials are known for their rigor and breadth. We also adopt the most comprehensive data integrity procedures to ensure that we capture, store and report data accurately.


Given the importance of work that we do, we employ only the brightest people. Over 700 employees, comprising research scientists and manufacturing professionals, work together to create vaccines and therapeutics with a twin focus on innovation and quality. Our world-class research and manufacturing capabilities, combined with our focus on the developing world diseases, position us for robust growth in the coming years.